[Video Profile] Interview with Eric Le Royer, CEO of EndoSense SA
Endosense is developing a catheter ablation treatment for cardiac rhythm disorders, including atrial fibrillation (AF). AF is the most common […]
Read more »Endologix Rejects Elliott Associates Buyout Bid
Regular Sentinel readers know I’m a fan of Endologix. The developer of a minimally invasive treatment for abdominal aortic aneurysms […]
Read more »Endocare and Galil Medical to Merge
Only months after Healthtronics withdrew its offer to acquire Endocare for $2.28 per share, Endocare and privately held Galil Medical […]
Read more »Abiomed: Record Revenue Driven by Impella
In June, Abiomed got the green light from the FDA to market its Impella 2.5 CAD, a minimally invasive ventricular […]
Read more »[Video Interview] Richard Taney, President & CEO of Delcath Systems
One of the central problems in using chemotherapy to treat cancer is its harmful effect on organ health. Lower dosages […]
Read more »Cyberkinetics Neurotechnology Nearing Paralysis
In a recent filing, Cyberkinetics Neurotechnology said it only had enough cash to last 30 days. If negotiations fail with […]
Read more »AngioDynamics Integrates Diomed’s EVLT
Having acquired onetime rival Diomed for a song, AngioDynamics has launched a new varicose vein therapy brand, VenaCure EVLT. The […]
Read more »Symphony Medical Raises $10 Million
Symphony Medical, a privately-held company developing novel biocompatible polymer therapies to treat chronic heart failure and atrial fibrillation has raised […]
Read more »CryoLife: EPS Increases, Revenues Up 21%
Revenues at CryoLife rose 21% to $26.8 million in the third quarter of 2008. Net income was $3.6 million, or […]
Read more »What’s Next for the Battered Laser Aesthetics Industry?
During times of economic malaise, discretionary income tends to decline. For many, it’s difficult to justify spending money on one’s […]
Read more »